Skip to main content

Agent Update - Individual Business

Posted by Medavie Blue Cross on August 24, 2023

Adapting to Changing Diabetes Treatment Landscape

In June, we communicated an initial plan to manage new trends in GLP-1 receptor
agonist drugs (primarily Ozempic which is approved by Health Canada only for
treatment of Type 2 Diabetes) that introduced Prior Authorization for new claimants.

This is to ensure these drugs are used for its intended purpose - Type 2 Diabetes, and
not for other conditions such as weight loss management. To ensure all our individual
members are treated equally and to ensure costs are being spent on their intended
purpose, Prior Authorization is now being extended to existing claimants, so that
anyone prescribed Ozempic will be required to provide proof of a Type 2 Diabetes

Starting September 1st, members impacted by this will receive a letter outlining their
alternatives and will be provided with a transitional grace period. Prior Authorization
for existing claimants will begin on November 1, 2023.

We appreciate your continued support as we continue to respond to this dynamic